DHA FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS

DHA 用于治疗原发性硬化性胆管炎

• 批准号: 7606960
• 负责人: Steven David Freedman
• 金额: $ 3.41万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606960
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis Transmembrane Conductance Regulator; Docosahexaenoic Acid n-3; Docosahexaenoic Acids; Fatty Acids; Functional disorder; Funding; Grant; Immune response; Institution; Oral Administration; Pathogenesis; Patients; Polyunsaturated Fatty Acids; Research; Research Personnel; Resources; Source; United States National Institutes of Health; primary sclerosing cholangitis

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypothesis of this study is that CFTR dysfunction may contribute to the pathogenesis of primary sclerosing cholangitis (PSC). Furthermore, correction of the fatty acid abnormality and changes in the innate immune response associated with CFTR dysfunction by oral administration of docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, might be an effective therapy for patients with PSC.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的假设是CFTR功能障碍可能有助于原发性硬化性胆管炎（PSC）的发病机理。此外，通过口服口服docosahexaenoic（DHA）（一种N-3多不饱和脂肪酸）对脂肪酸异常的纠正以及与CFTR功能障碍相关的先天免疫反应的变化可能是PSC患者的有效疗法。